The concomitant utilization of oxycodone HCl with all cytochrome P450 3A4 inhibitors could end in a rise in oxycodone plasma concentrations, which could raise or prolong adverse reactions and may result in most likely lethal respiratory depression. In addition, discontinuation of the concomitantly employed cytochrome P450 3A4 inducer might end in a